Dyadic (DYAI) Q1 2026 Earnings Call Transcript

Image source: The Motley Fool.

DATE

Wednesday, March 25, 2026 astatine 5 p.m. ET

CALL PARTICIPANTS

• President and Chief Operating Officer — Joseph Hazelton

• Chief Executive Officer — Mark Emalfarb

• Chief Financial Officer — Ping Rawson

Need a punctuation from a Motley Fool analyst? Email [email protected]

Full Conference Call Transcript

Joseph Hazelton: Thanks, Ping, and convey you, everyone, for joining america today. As we precocious held our afloat twelvemonth 2025 net call, today, we privation to physique connected the updates we provided successful March by focusing connected the continued operational and commercialized advancement we're making crossed the concern and wherefore we judge Dyadic is progressively good positioned for the future. Over the past respective years, we person worked to alteration Dyadic from a level exertion institution into a commercially focused biotechnology institution susceptible of generating recurring revenues from products, partnerships, licensing opportunities and strategical collaborations.

While we're inactive successful the aboriginal stages of that transition, we judge the advancement made during 2025 and into 2026 demonstrates that the concern contiguous is materially antithetic than it was adjacent a twelvemonth ago. Importantly, products enabled by our microbial accumulation platforms are present entering commercialized channels. We person products launched, products being shipped, products being sampled by customers and products opening to make revenues done nonstop sales, OEM distribution, milestone payments, profit-sharing arrangements and strategical partnerships. For investors, the cardinal constituent is that Dyadic is gathering aggregate imaginable paths to gross instauration alternatively than relying connected a azygous merchandise oregon marketplace opportunity.

A beardown illustration is Proliant Health & Biologics' commercialized motorboat of Albufree Dx recombinant quality albumin produced utilizing Dyadic's level technology. Dyadic is eligible to person a stock of the profits from merchandise sales. We judge the value of this motorboat extends beyond the economics themselves. It demonstrates that the established manufacture participants are consenting to commercialize products produced utilizing our exertion level and bring them into commercialized channels. Similarly, Inzymes has present commercialized recombinant non-animal bovine chymosin aft successfully achieving developmental milestones. This is different important validation constituent for our exertion and commercialization models. As further partners bring products to market, we judge consciousness and involvement successful our platforms volition proceed to increase.

Since these launches and concern announcements, we've seen increasing inbound involvement from imaginable partners, distributors and customers evaluating our exertion for further proteins and enzymes crossed beingness sciences, nutrient and nutrition and concern applications. Our strategy is astir -- centered astir leveraging our proprietary C1 and Dapibus microbial accumulation platforms to nutrient animal-free proteins and enzymes for ample and increasing planetary markets wherever scalability, manufacturing economics, proviso concatenation reliability and sustainability matter. We judge our exertion is peculiarly good suited for these markets due to the fact that the galore products we people necessitate unchangeable manufacturing, competitory economics and accordant quality. Traditional accumulation systems tin beryllium expensive, hard to standard oregon babelike connected animal-derived inputs.